Gilead profits rise to €631m driven by 9% jump in turnover

Gilead mainly produces drugs to combat HIV and Hepatitis C, while its Veklury medicine is a treatment for covid-19.

Last year, Gilead paid out cash dividends of $2.6bn to its immediate parent, Gilead Biopharmaceutics US. Picture: Larry Cummins

Pre-tax profits at the main Irish unit of pharmaceutical giant Gilead last year increased more than threefold to $725.96m (€631m).

New accounts show that Cork-based Gilead Sciences Ireland UC (GSIUC) recorded a sharp jump in profits, with revenues increasing by 9% from $6.55bn to $7.11bn.